Radius Stock Rides Rollercoaster After ASBMR Bone Data
This article was originally published in Scrip
Radius Health Inc. continues to report positive results for its osteoporosis therapy abaloparatide, but the company's stock has been on a somewhat bumpy ride since results were presented at the recent American Society of Bone and Mineral Research (ASBMR) meeting.
You may also be interested in...
Flagship Ventures has recruited former Merck Chief Medical Officer Michael Rosenblatt as its CMO to mentor biopharma startups in the venture firm's portfolio – a hire that appears to be the first of its kind.
Public Company Edition: NewAmsterdam grossed $328m in its SPAC merger, while Liminatus may raise up to $316m in a new SPAC deal. Also, Intellia and Iveric grossed $300m each in follow-on offerings, bluebird sold a PRV for $102m and MEI ends zandelisib development resulting in layoffs.
The company believes the Phase III Clarity AD results offer a high level of evidence that may convince the Centers for Medicare and Medicaid Services to change its stance on anti-amyloid antibodies for lecanemab.